Novo Nordisk tests grand acquisition in phase III trial

Pharmaceutical giant Novo Nordisk is testing a hormone test for diagnosing children with growth hormone deficiency in a phase III trial. Novo Nordisk bought the test back in 2018 for DKK 1.2bn as part of the firm's market race where it's competing with Ascendis Pharma on producing growth hormones.

Photo: Novo Nordisk Pharmatech/PR

Novo Nordisk has great expectations for the growth hormone market, where the pharmaceutical company is currently in competition with Danish biotech company Ascendis Pharma.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs